Early Release - Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC

Early Release - Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020 - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC

Volume 26, Number 9—September 2020

Research Letter

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020

On This Page

Research Letter

---

Suggested Citation

Tables

Table

Downloads

RIS [TXT - 2 KB] 

Article Metrics

Metric Details

Related Articles

Autopsy of Patient with COVID-19, Japan

---

Detection of SARS-CoV-2 RNA on Surfaces

---

Large Outbreak of COVID-19 among Wedding Attendees

---

More articles on Coronavirus, COVID-19

Avnish Sandhu, Glenn Tillotson, Jordan Polistico, Hossein Salimnia, Mara Cranis, Judy Moshos, Lori Cullen, Lavina Jabbo, Lawrence Diebel, and Teena Chopra 

Author affiliations: Detroit Medical Center, Detroit, Michigan, USA (A. Sandhu, J. Polistico, H. Salimnia, M. Cranis, J. Moshos, L. Cullen, L. Jabbo, T. Chopra); Wayne State University School of Medicine, Detroit (A. Sandhu, J. Polistico, H. Salimnia, L. Diebel, T. Chopra); GST Micro LLC, Henrico, Virginia, USA (G. Tillotson)

Suggested citation for this article

Abstract

We describe 9 patients at a medical center in Detroit, Michigan, USA, with severe acute respiratory syndrome coronavirus 2 and Clostridiodes difficile. Both infections can manifest as digestive symptoms and merit screening when assessing patients with diarrhea during the coronavirus disease pandemic. These co-infections also highlight the continued importance of antimicrobial stewardship.

Coronavirus disease (COVID-19), which is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), predominantly includes pulmonary symptoms; however, <10% of cases also include gastrointestinal events, including abdominal pain, diarrhea, and vomiting (1–4). During the COVID-19 pandemic, clinicians must be vigilant of co-infections in patients with COVID-19.

Several studies have collected data on concomitant antibiotic use in patients with COVID-19. A single-center study of 52 critically ill patients cited hospital-acquired infection in only 7 (13.5%) patients, yet 49 (94%) patients received antibiotic therapy (5). Another study, which analyzed 113 deceased patients from a cohort of 799 moderate-to-severely ill COVID-19 patients during January 13–February 12, 2020, reported that 105 (93%) deceased patients and 144 (89%) survivors had received empiric antibacterial therapy with either moxifloxacin, cefoperazone, or azithromycin (6). These antibiotics are strongly associated with C. difficile infection (CDI) (7). We report an observation of CDI as a co-occurrence or sequalae of overuse of antibiotics in COVID-19 patients.